![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextgreen.png)
![Open Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_open_medium.gif)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltextred.png)
![Restricted Access](https://i-scholar.in/lib/pkp/templates/images/icons/fulltext_restricted_medium.gif)
Formulation and Evaluation of Solid Lipid Nanoparticle Based Transdermal Drug Delivery System for Alzheimer’s Disease
Subscribe/Renew Journal
Solid lipid nanoparticles (SLN) loaded formulation as an alternative to oral and parenteral delivery of rivastigmine tartarate (RT), a water-soluble drug by using Precirol ATO 5 and tween 80. The SLN prepared by hot high pressure homogenization method. RT-loaded SLN were stable up to one month of storage .The SLN was found to be zeta potential value of -10 mV, polydispersity index was found in the range 0.3-0.6 with average particle size distribution of 214 nm. The encapsulation efficiency (EE %) was found to be 59.23%. The folding endurance, thickness, drug content uniformity of RT-loaded transdermal patch was found to be 160±1.05 folds, 0.26±0.05mm, 98.63±0.16% respectively. The percent moisture content, percent moisture loss, percent elongation break test was found to be 4.2±0.26%, 3.9±0.31%, 9.23±0.93% respectively. The ex vivo skin permeation and in vitro drug release kinetics has shown 96.90±0.69% permeation and 95.70±0.87% drug release respectively. The RT-SLN loaded transdermal patch was prepared using Eudragit RS100 and Eudragit RL100 and PEG 400 as plasticizer. Formulation was optimized by using full 32 factorial design expert 10. Ex vivo study showed maximum drug release with 24 hours.
Keywords
Rivastigmine Tartarate, Precirol ATO 5, Tween 80, Solid Lipid Nanoparticles, High Pressure Homogenization, Eudragit RS 100, Eudragit RL 100.
Subscription
Login to verify subscription
User
Font Size
Information
![](https://i-scholar.in/public/site/images/abstractview.png)
Abstract Views: 251
![](https://i-scholar.in/public/site/images/pdfview.png)
PDF Views: 2